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Abstract (246 words) 
Rationale 
Idiopathic and hereditary pulmonary arterial hypertension (PAH) are rare but comprise a genetically 
heterogeneous patient group. RNA-sequencing linked to the underlying genetic architecture can be 
used to better understand the underlying pathology by identifying key signalling pathways and 
stratify patients more robustly according to clinical risk. 
Objectives 
To use a three-stage design of RNA discovery, RNA validation/model construction and model 
validation to define a set of PAH-associated RNAs and a single summarising RNA model score. To 
define genes most likely to be involved in disease development, we performed Mendelian 
randomisation (MR) analysis. 
Methods 
RNA-sequencing was performed on whole blood samples from 359 patients with idiopathic, 
heritable and drug-induced PAH and 72 age- and sex-matched healthy volunteers. The score was 
evaluated against disease severity markers including survival analysis using all-cause mortality from 
diagnosis. MR used known eQTL and summary statistics from a PAH GWAS. 
Measurements and Main Results  
We identified 507 genes with differential RNA expression in PAH patients compared to controls. A 
model of 25 RNAs distinguished PAH with 87% accuracy (AUC 95% CI: 0.791-0.945) in model 
validation. The RNA model score was associated with disease severity and long-term survival 
(p=4.66x10-6) in PAH. MR detected an association between SMAD5 levels and PAH disease 
susceptibility (OR:0.317, 95%CI:0.129-0.776, p=0.012). 
Conclusions 
A whole blood RNA signature of PAH, which includes RNAs relevant to disease pathogenesis, 
associates with disease severity and identifies patients with poor clinical outcomes. Genetic variants 
associated with lower SMAD5 expression may increase susceptibility to PAH.  
 
Current word count: 3375 (main text)  
Background 
Pulmonary arterial hypertension (PAH) is associated with vasoconstriction and occlusion of distal 
pulmonary arteries, characterised by endothelial damage, smooth muscle and fibroblast 
proliferation, and inflammation. Increased pulmonary vascular resistance leads to right heart failure, 
with survival rates estimated at 52-75% at 5-years, even with modern day therapy(1). The rate of 
deterioration and response to therapy varies between patients, driving a search for better predictors 
of clinical outcome and tools to inform drug selection. Molecular profiling using multiple omics 
technologies offers greater granularity than standard clinical phenotypes for characterising PAH 
patients and could improve initial risk stratification, treatment selection and monitoring as well as 
providing insights into biological pathways not yet targeted by current therapies(2-4). 
Transcriptome profiling through RNA sequencing permits a comprehensive analysis of gene 
expression in tissue samples. Whole blood RNA analysis offers an alternative “liquid biopsy” to lung 
biopsy, which carries a high risk in PAH, and can be performed sequentially. This approach can also 
investigate immune mechanisms in PAH that have recently been highlighted (5). Previous studies of 
blood RNA in PAH have been limited by patient numbers and the use of microarrays, which are less 
sensitive than high quality RNAseq and limited by the probe set of each specific array. A recent 
meta-analysis of these microarray studies identified some consistent differentially expressed genes 
not appreciated in individual studies(6). Explanted lung tissues from late-stage PAH patients have 
also shown differences in RNA profiles(7). The results from both studies remain to be validated in 
independent cohorts. 
The aim of this study was to characterise gene pathways associated with PAH and to assess their 
association with disease heterogeneity, specifically in terms of disease severity and outcomes 
including response to vasodilators and mortality, and genetic background. We compare gene 
expression in whole blood samples from 359 patients with idiopathic, heritable or drug induced PAH 
from the UK PAH Cohort study with 72 age- and sex-matched healthy volunteers without any cardiac 
or respiratory disease as controls. Using equal distribution of samples into a three-stage design, we 
identified reproducible RNA expression differences by RNAseq. Two distinct computational 
approaches were used to estimate white blood cell (WBC) fractions and thus account for the 
potential effect of different cell numbers on gene transcript levels across samples. A predictive 
statistical model that combined gene expression differences performed well at identifying PAH 
patients in a separate case-control analysis. The RNA-based score was also associated with disease 
severity and clinical outcomes (all-cause mortality). Enrichment of genetic variants that determine 
the levels of PAH RNAs was detected, implicating these RNAs in the pathogenesis of the disease. 
  
Methods 
Comprehensive methods are included in the online supplement. 
Study participants and sample analysis 
Patients with idiopathic, heritable or drug-induced pulmonary arterial hypertension (referred to 
throughout as PAH) were recruited from expert centres across the UK as part of the PAH Cohort 
study (www.ipahcohort.com). In each case, diagnosis was confirmed by right heart catheterisation 
following established international guidelines(1), which remained unchanged for the duration of this 
study. Healthy volunteers were recruited at the same centres and samples processed using the same 
standard operating procedure at all sites. All individuals gave written, informed consent with local 
ethical committee approval. Whole blood (3 ml) was collected in Tempus™ Blood RNA Tubes, and 
RNAsequencing performed using established Illumina methodologies (see online supplement for 
further details). Genomics data were obtained from a published PAH genome-wide association 
study(8). 
359 PAH patients were randomised into 3 data analysis groups for RNA discovery (n=120), RNA 
validation (n=120) and model validation (n=119). Each of these 3 groups were then compared to an 
independent set of age- and sex-matched healthy volunteers as controls (n=24 in each set; Table 1 
and Supplementary Figure 1).  
RNAseq Data analysis 
Fastq files (raw reads from RNAseq) were analysed using Salmon v0.9.1(9) and GENCODE release 28 
to produce transcript abundance estimates which were converted to gene expression data using 
tximport in R with Rstudio(10). Quality control is detailed in the supplement. 
RNAseq analysis of tissues with mixed cell types such as blood can be affected significantly by the 
cell composition of each sample. Two different computational approaches, CIBERsort(11) and 
quanTIseq(12), were used to predict white blood cell (WBC) profiles associated with PAH, which 
were included as covariates in secondary differential gene expression analyses (see supplement). 
Differential expression analysis was performed using edgeR v3.22.5(13) correcting for the 3 principal 
components, which each explained more than 1% of the variance in the dataset. Differentially 
expressed genes were defined in analyses both with and without WBC fractions as covariates in 
distinct discovery and validation sample sets. These sets were then combined and only significant 
genes (p<0.05) and directionally consistent in the initial analyses and meeting false discovery rate 
multiple test corrections (based on all detected genes, α=0.1) in the combined analysis were taken 
forward. 507 genes meeting these criteria were considered to generate a model to distinguish PAH 
from controls. Subset selection of RNAs which best distinguish PAH in combination was performed 
by least absolute shrinkage and selection operator (LASSO) regression analysis, using the glmnet 
v2.0-18 package from CRAN, with k-fold cross-validation (k=10) selecting the largest value of lambda 
such that error is within 1 standard error of the minimum. This produces an RNA score from a linear 
weighted combination of the mRNAs identified by the LASSO analysis. Receiver operating 
characteristic (ROC) analysis was performed using the pROC v1.14.0 package from Bioconductor(14).  
Survival curves from date of diagnostic right heart catheterisation were constructed using Kaplan-
Meier estimates with left-truncation for date of sampling for this study to correct for survival bias. 
Differences in survival estimates were assessed by log rank test. RNA scores were also compared 
across disease severity markers 6-minute walk test (Spearman’s rank), WHO functional class 
(Kruskal-Wallis ANOVA) and by cardiac biomarkers (circulating BNP or NT-proBNP as available, using 
cut-offs from European guidelines for risk assessment(1)). 
Functional annotation and enrichment of the genes associated with PAH was performed using DAVID 
(david.ncifcrf.gov) and Ingenuity Pathway Analysis (IPA®) using in-built false discovery rate 
corrections for multiple tests.  
Mendelian randomisation analysis using all independent genome-wide significant whole blood 
expression quantitative trait loci (eQTLs) from two published studies(15, 16) and PAH association 
from our published GWAS(8) was performed using the TwoSampleMR package(17).   
Results 
Identification of RNAs differentially expressed in PAH patients compared to controls 
The three-stage study design is depicted in Figure 1. 507 RNAs were significantly different (p<0.05) 
between PAH and controls with directional concordance in both discovery and validation analyses 
(Figure 2 and Supplementary Table 3) before and after accounting for WBC fractions (see Methods 
and Supplementary Tables 1-3 and Supplementary Figure 2). All 507 genes were included after 
accounting for multiple testing (FDR α<0.1, Supplementary Table 3). None were associated with 
exposure to the main PAH therapies (see supplement for further details). These included RNAs in 
pathways relevant to PAH; for example, SMAD5 (Mothers Against Decapentaplegic Homolog-5), 
encoding a downstream mediator of signalling of BMPR2(3), was reduced in PAH patients (Figure 2C), 
consistent with documented reduced BMPR2 signalling in this condition, and the transient receptor 
potential cation channel, TRPC1 (Figure 2D), also associated with the development of PH(18) was also 
reduced in patients. 
A set of differentially expressed RNAs relevant to PAH pathobiology were selected for validation of 
RNAseq quantification by qPCR, namely, NRG1, TRPC1, FBLN2, SESN1, SMAD5 and CCND3. SPAST was 
also selected for its stability across samples as a potential control gene (see Methods for details). All 
qPCR measurements correlated significantly with RNAseq quantification (p<0.05, Spearman’s rho = 
0.3 - 0.89, Supplementary Table 4). 
Patients and controls from the RNA discovery and validation analyses were then combined and 
LASSO analysis was used to determine the combination of RNAs that performed best in 
discriminating PAH patients from controls in a single model; this analysis yielded 25 RNAs 
(Supplementary Table 5). The model was then tested in an independent validation set (n=119 PAH 
patients and n=24 controls) and demonstrated an area-under-the-curve of 0.868, 95% CI: 0.791-
0.945 (Figure 3). The optimum cut-off for identifying PAH with the LASSO model of 1.768 recognised 
88.9% of patients with 72.2% specificity. 
Survival association of RNA model in clinically diagnosed idiopathic and heritable PAH 
We next examined whether the RNA model was also associated with patients with the poorest 
outcomes, using all 359 patients. The optimum cut-off (1.910) for identifying PAH non-survivors with 
the LASSO model separated PAH patients into low- and high-risk groups in survival analysis (Figure 
4A-B and Supplementary Figure 3).  
To determine which of the 25 transcripts in the model were responsible for the association with 
survival, we tested each transcript for associations with all-cause mortality during follow-up. After 
false discovery rate correction for multiple testing, three intronic long non-coding RNAs (RP4-
751H13.6/ATP6V0E2-AS1, RP4-534N18.4/AL136115.3/Lnc-PTP4A2-13, RP11-701H24.5/lnc-SNRPN-
1:6) were associated with survival in all the PAH patients analysed and cut-offs distinguished high- 
and low-risk patient subgroups (Supplementary Table 6 and Supplementary Figure 4). 
To further characterise the RNA signature, we analysed its association with three clinical measures 
of disease severity – WHO functional class, exercise capacity (6-minute walk) and cardiac biomarkers 
(BNP or NT-proBNP). We found a significant difference in RNA scores between patients in different 
WHO functional classes (p= 0.008; Figure 4C) and BNP/NT-proBNP levels (p= 5.10x10-4; Figure 4D) 
and a significant negative correlation with exercise capacity (Spearman’s rho= -0.256, p= 8.7x10-5). 
RNA profiles in responders to vasodilator therapy 
Several RNAs have been proposed as biomarkers for identifying vasoresponders to calcium 
antagonists using cultured lymphocytes(19). We compared the transcriptome of the 17 
vasoresponders and 223 non-vasoresponders in the RNA discovery and first validation groups but 
found no transcripts consistently distinguished responders and non-responders, and that none of 
the previously implicated RNAs were even nominally different (Supplementary Table 7). 
Comparison with differentially expressed genes identified in previous studies 
A meta-analysis of previous transcriptomic studies in blood samples from PAH patients(6) and a 
study of PAH lung tissue samples(7) were compared to results from the current RNAseq analysis.  
416 out of the 507 top dysregulated genes from the current RNAseq study were present in the PAH 
blood transcriptomic meta-analysis(6). Out of those, 300/416 (72%) were directionally consistent 
with results from the current RNAseq study. 126/300 (42%) of these were nominally significant and 
70 met FDR corrected significance. 37/70 genes also met FDR corrected significance in the IPAH 
subgroup analysis from that same study (Supplementary Table 8).  
372 out of the 507 top dysregulated genes from the current RNAseq study were present in the lung 
tissue microarray study and 161/372 (43%) were also directionally consistent. 41/161 (25%) genes 
were nominally significant and 26 met FDR corrected significance (Supplementary Table 9). Only one 
gene was found to be dysregulated in PAH patients across all three studies; AMD1 (encoding a 
polyamine biosynthesis intermediate enzyme, adenosylmethionine decarboxylase 1) was 
consistently lower in PAH. 
Functional characterisation of RNAs related to PAH 
Of the 507 RNAs found to be differentially expressed in PAH, 435 were present in the functional 
annotations in DAVID. Enrichment of DNA-binding transcription factors (TFs), such as hypoxia-
inducible factor 1α (HIF1α) and Krüppel-like factor 10 (KLF10), and many zinc-finger containing TFs 
was observed compared to a background of the genes detected (Supplementary Table 10). The 
Ingenuity Knowledge Base mapped 505/507 transcripts. Double-stranded DNA repair, T cell 
receptor, PI3K signaling in B lymphocytes, the role of JAK family kinases in IL6-type cytokine signaling 
and hypoxia signaling were among the top canonical pathways identified by IPA® (Supplementary 
Figure 5; Supplementary Table 11). AMD1, the only gene in common between the current RNAseq 
study, the recent lung tissue microarray study and the gene expression meta-analysis, was part of 
the top IPA® gene network (Supplementary Figure 6).  
Mendelian randomisation (MR) analysis for association of RNAs with PAH development 
To determine which of the 507 RNAs associated with PAH are most likely to be causal in disease 
pathogenesis, we performed a two-sample MR analysis using whole blood expression quantitative 
trait loci (eQTL) from two population-based studies(15, 16) and summary statistics from a published 
PAH genome-wide association study of 2085 PAH patients and 9659 controls(8). MR analysis 
determines whether genetic variation associated with a trait (e.g. high or low RNA expression) is 
itself associated with a phenotype, in this case the development of PAH. In this exploratory analysis 
where eQTL were available for 293/507 RNAs, two genes, SESN1 (Sestrin-1) and SMAD5, reached 
nominal significance using eQTL in both data sets(15, 16); eleven more reached nominal significance 
using eQTL from one or other of the two studies (Supplementary Tables 12 & 13). 
The SMAD5 eQTL SNP rs4146187 was clearly associated with SMAD5 RNA levels in PAH patients in 
this study (p=3.56x10-6, Figure 5; gnomAD database allele frequency in non-Finnish European 
Population = 0.275). Patients with the A/A genotype had comparable SMAD5 RNA levels to controls, 
whereas patients with the C/C genotype had a median 18% lower SMAD5 RNA level. The C/C 
genotype was present in 49.4% of PAH patients, and in the PAH genome-wide association study(8), 
each copy of the A allele (associated with higher SMAD5 levels) was associated with an 8.5% 
reduction in the risk of developing PAH (odds ratio:0.915, 95% confidence intervals:0.846-0.990, 
p=0.0266). SMAD5 levels were similarly reduced in PAH patients with and without pathogenic 
BMPR2 variants (Supplementary Figure 7A), supporting the observation that impaired signalling in 
the BMPR2 pathway is more common in PAH than rare mutations in BMPR2 suggest. The PAH RNA 
model score was similarly elevated in PAH patients with and without pathogenic BMPR2 variants 
(Supplementary Figure 7B). 
Discussion 
Here we report a RNA signature that separates idiopathic and heritable PAH from healthy 
individuals. The signature also stratifies patients according to disease severity and risk of early death, 
adding plausibility to its association with PAH. Several of the discriminating mRNAs encode 
transcription factors, including SMAD5, HIF-1α and KLF10. Mendelian randomisation analysis to 
integrate genomic data and identify underlying pathogenic signalling pathways revealed that genetic 
variants associated with lower expression levels of SMAD5 are more common in PAH patients. 
Mendelian randomisation is a powerful tool for separating cause from consequence, as an 
individual’s genetic status pre-dates the development of PAH. We harnessed genetic data from a 
published international genome-wide association study(8) and information on previously identified 
eQTL, common genetic variants which alter gene expression levels, from large published studies in 
whole blood RNA samples(15, 16). The identification of SMAD5 by this unbiased strategy has 
biological plausibility as SMAD5 encodes an intracellular transcriptional modulator which is activated 
by ligand binding of BMPR2, the most common genetic risk factor in heritable PAH(3). SMAD5 also 
has BMP-independent roles, including regulation of cellular metabolism, directly interacting with 
hexokinase to increase glycolysis and responding to changes in intracellular pH(20). SMAD5 also 
controls levels of the master iron regulator hepcidin(21), which may be elevated and drive iron 
deficiency associated with poor outcomes in PAH(22). Novel therapeutics under development target 
restoration of BMPR2 signalling in a variety of ways, including ligand or co-activator replacement and 
allowing read-through of premature stop codons(23-25). Whole blood SMAD5 profiling may 
represent an accessible measurement of BMPR2 pathway dysfunction in PAH patients. 
We were able to externally validate our findings with a meta-analysis of published PAH blood 
transcriptome studies(6) and a PAH lung RNA profiling study(7). The concordance of our whole blood 
RNAseq findings is better with blood transcriptomics than with lung tissue data, as might be 
expected.  AMD1 was the only gene consistently dysregulated in both these studies and our dataset, 
with lower levels in PAH samples in all three studies. AMD1 encodes a key enzyme controlling the 
supply of decarboxylated S-adenosylmethionine for polyamine biosynthesis and is regulated by 
several mechanisms, including increased protein degradation in the presence of elevated 
polyamines and the inhibition of mRNA translation by spermidine and spermine(26). We have 
previously demonstrated that elevated circulating levels of polyamine metabolites, such as acisoga, 
4-acetamidobutanoate and N-acetylputrescine, are associated with poor outcomes in PAH(4). 
Reduced AMD1 expression in PAH patients may be in part due to negative feedback from elevated 
polyamines. These data contrast with observations in hypoxic rodents. Amd1 expression is increased 
in hypoxic animals and both AMD1+/- mice and mice treated with the AMD1 inhibitor, SAM486a, 
were partially protected from the development of hypoxic PH(27). Interestingly, TRPC1 transcript 
levels were also reduced in PAH, in contrast to findings in hypoxic mice(18). This might reflect the 
limitations of the hypoxic rodent as a model of human PAH. Support for further investigation of 
polyamine metabolism in PAH comes from the recent association of rare deleterious mutations in 
ATP13A3 with PAH(3). ATP13A3 is linked with polyamine biosynthesis and is a potential, target for 
drug development(28). 
Many of the transcripts that passed robust statistical evaluation in this study are novel. We 
identified 3 specific lncRNAs that are reduced in PAH and associated with poor outcomes. These 
transcripts are not well studied and their role in regulating lysosomal proton pump 
protein ATP6V0E2, protein tyrosine phosphatase PTP4A2 or small nuclear ribonucleoprotein-
associated protein N remain to be established. Their association with survival selects these out as 
worthy of further investigation. In addition to suggesting biological relevance, the association of the 
RNA model, developed to distinguish PAH from controls, with survival and disease severity in PAH 
patients suggests that the differences observed could be useful to identify patients who may require 
a more aggressive treatment strategy, such as upfront, triple therapy(29). This strategy could also be 
used to prioritise patients more likely to have events to power clinical trials. RNA profiles and in 
particular, RNAs with known eQTLs, could be of further use in clinical trial design to identify patients 
more likely to respond to specific therapeutics. It would be of great interest, for example, to observe 
whether patients with lower SMAD5 levels, or simply with the variant associated with lower SMAD5 
levels, showed a differential response to novel therapeutics targeting relevant signalling, such as the 
TGF-beta ligand trap, Sotatercept.  
There is considerable interest in developing a biochemical test to identify PAH patients who respond 
well to calcium antagonists that would supersede the current test; namely, an acute vasodilator 
challenge while undergoing cardiac catheterisation.  In contrast to previous reports, we were unable 
to demonstrate the association of a peripheral transcript signature to vasoresponder status, 
including previously studied RNAs(19). A strength of our study is the number of patients studied. 
Previous reports have relied on much smaller patient numbers. That we were able to demonstrate 
consistency between our main analysis results and those of a recently-published meta-analysis of 
PAH blood transcriptome studies(6) suggests our methodological approaches are robust.  
One of the limitations of sampling whole blood to derive transcripts is that samples comprise a 
mixed population of cells. We used established deconvolution methods to correct for potential 
confounding in RNA expression analysis. In support of the validity of this approach, we noted altered 
numbers of regulatory T cells and CD8-positive T cells in PAH patients, consistent with previous 
reports (30, 31), although there is debate on precise changes in cell subpopulations and this may be 
due in part to differing methodologies and definitions of cell types(32). 
This study does not assess the role of post-translational modifications in the pathogenesis of PAH, 
which could add further information to the circulating transcriptome. It is important that further 
mechanistic studies consider the role of the genes highlighted in this study in the tissues of primary 
interest, namely, the lung and heart. The study design included more patient samples than controls 
to account for the higher heterogeneity typically observed in patient populations. This heterogeneity 
is observed in the overlap in boxplots of individual RNA levels or scores between subsets of PAH 
patients and controls and emphasises the importance of using any molecular markers in 
combination with best practice clinical assessments. We chose to use LASSO regression modelling 
not only as it is known to perform well in these kinds of datasets but also because it is widely applied 
and often easier to interpret than other methodologies. Another consideration is that the patients 
studied here were prevalent cases. Moreover, all the patients recruited had a clinical diagnosis of 
idiopathic, heritable or drug-induced PAH. It would be of interest to sample patients with other 
presentations of PAH and other cardiopulmonary diseases to better understand the clinical utility of 
our RNA signature. 
In summary, we report a whole blood RNA profile that distinguishes PAH patients from healthy 
controls and reflects disease severity. Integration with genomic data suggests that SMAD5 is 
important in the development of PAH, prioritising restoration of normal SMAD5 function as a target 
for therapeutic intervention.   
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  A - RNA discovery B - RNA validation C - Model validation 
 Controls PAH Controls PAH Controls PAH 
Female 17 89 16 80 17 86 
Male 7 31 8 40 7 33 
Age  
43.9 (30.2 - 
53.4) 
45.2 (35.7 - 
55) 
45.1 (31 - 
53.5) 
43.2 (33.3 - 
54.8) 
44.4 (31.7 - 
51.6) 
47.1 (36.7 - 
61.2) 
PAH Patient characteristics in A, B & C  median (25% - 75%) or counts 
Age at diagnosis 44.8 (34.3 - 58.1) 
Female/Male 255 / 104 
Ethnicity: white/other 314 / 45 
WHO functional class: I/II/III/IV 36 / 138 / 155 / 18 
Six-minute walk distance, m 330 (224.5 - 411) 
Mean pulmonary artery pressure, mmHg 53 (46 - 61) 
Mean right atrial pressure, mmHg 8 (6 - 12) 
Pulmonary capillary wedge pressure, mmHg 10 (7 - 12) 
Cardiac output, L/min 3.8 (3.05 - 4.9) 
Cardiac index, L/min/m2 2.07 (1.68 - 2.57) 
Pulmonary vascular resistance, Wood units 11.55 (7.93 - 15.78) 
Years since diagnosis sampled 3.95 (1.38 - 7.7) 
Years survived since sampling 3.14 (2.3 - 3.67) 
Years survived since diagnosis 6.99 (4.19 - 10.88) 
Vasoresponders 21 
 
Table 1 - Basic demographics of controls and PAH patients in three analysis groups, and more detailed clinical 
characteristics including disease severity of PAH patients as a cohort. Controls are healthy volunteers without any 
cardiac or respiratory disease. 
 
 
 
 
 Figure 1 – Study design. 359 consecutively recruited PAH patients from the UK National Cohort study of PAH were 
randomised into 3 groups. Age and sex-matched controls for each group were then identified from the same study. 
The first two groups were analysed separately for RNA discovery and RNA validation and then combined for 
modelling of the best combination of RNAs to distinguish between controls and PAH. This model was then tested in 
the final group of individuals. All patients were combined for subsequent clinical analyses. 
 
 
 
  
  
Figure 2: Identification of RNAs with different levels in PAH patients and controls. A&B. Volcano plot of RNA log fold 
differences between PAH and controls in A. discovery and B. validation analyses. Selected genes were identified in 
further analyses presented throughout manuscript including modelling, external validation and Mendelian 
randomisation. C-D. Boxplots of C. SMAD5 and D. TRPC1 levels (log10 reads) in controls and PAH patients in the RNA 
discovery, validation and model validation (validation 2) analysis groups. 
 
 
 
 Figure 3 – LASSO model performance in an independent validation group of age- and sex-matched subjects. A. 
Boxplot showing LASSO model scores for controls (n=24) and PAH patients (n=119). B. Receiver operating curve 
showing the performance of LASSO model scores for determining PAH status in the model validation group.  
 
  
  
            
Figure 4 - Diagnostic RNA model and survival in PAH. A. Boxplot of LASSO model score in controls and PAH patients 
separated by survival status during follow-up. Dashed line shows the cut-off that identified 88.9% of non-surviving 
PAH patients. B. Kaplan-Meier survival plot separating patients on basis of the 88.9% sensitive cut-off. C. Boxplot of 
RNA model score in healthy volunteers and PAH patients divided by WHO functional class. D. Boxplot of RNA model 
score in PAH patients divided by presence of low, intermediate or high levels of cardiac biomarkers BNP (<50 pg/ml, 
50-300 pg/ml or >300pg/ml) or NT-proBNP (<300 pg/ml, 300-1400 pg/ml or >1400 pg/ml), as per European 
guidelines for PAH assessment. 
  
  
 
 
Figure 5 - Whole blood RNA levels of SMAD5 in controls, and PAH patients stratified by genotype at the SMAD5 eQTL 
rs4146187. 
 
